Independent Urology Groups Unite to Protect Physician Autonomy and Financial Stability
Chicago, Saturday, 7 November 2026.
Despite sixty percent of U.S. counties lacking a urologist, independent practices face severe Medicare reimbursement cuts, prompting leaders at LUGPA’s Chicago meeting to champion AI and regulatory reform.
Independent Urology Practices Under Financial Pressure
Independent urology practices in the United States are navigating a precarious financial landscape as Medicare reimbursement cuts loom, threatening their operational viability despite serving critical healthcare needs. At LUGPA’s 18th Annual Meeting in Chicago—concluding today—industry leaders emphasized that a scheduled 2.5% Medicare conversion factor cut in 2027, combined with prior authorization burdens and impending Part B drug price negotiations in 2028, will exacerbate financial strain on these physician-led groups [3]. Gary Kirsh, MD, president emeritus of The Urology Group and LUGPA’s health policy chair, noted that while 2026 has not seen monumental policy shifts, the cumulative impact of these regulatory changes could destabilize independent practices already operating on thin margins [3]. ‘The looming issue of Medicare price negotiation for Part B infusion drugs, which begins in early 2028, is only about a year away,’ Kirsh warned, highlighting the urgent need for legislative intervention [3].
Geographic Disparities in Urology Access
The geographic maldistribution of urology services compounds the financial challenges facing independent practices. As of 2024–2025, approximately 60% of U.S. counties lacked any urologist, underscoring the critical role these practices play in delivering care to underserved communities [3]. This workforce shortage not only limits patient access but also creates opportunities for independent urologists to fill gaps, particularly in rural and underserved areas. However, the financial sustainability of these practices is increasingly at risk. Kirsh emphasized that workforce shortages in rural and underserved areas are ‘a tremendous problem that will not be solved quickly or easily,’ further straining the ability of independent practices to maintain operations without adequate reimbursement [3].
Policy Reforms Offer Limited Relief
While some policy changes have provided temporary relief, independent urology practices continue to face systemic challenges. The Centers for Medicare & Medicaid Services (CMS) finalized reforms to the 340B program and extended site-neutral payments to non-contrast imaging services, policies viewed favorably by independent practice advocates [3]. However, these measures are not sufficient to offset the broader financial pressures. Experian Health’s 2026 State of Claims report revealed that 40% of providers face at least a 10% claim denial rate, 78% report more frequent payer policy changes, and 64% experience longer reimbursement times, further squeezing cash flow for independent practices [5]. These operational hurdles make it difficult for practices to invest in technology, staff, or expanded services, despite the growing demand for urology care.
Private Equity and Market Consolidation Intensify
The consolidation of independent urology practices into larger platforms is accelerating, driven by private equity investment and the financial pressures facing smaller groups. A $1.9 billion transaction saw Cardinal Health acquire Solaris Health, Urology America, and Potomac Urology, expanding the Urology Alliance to approximately 750 physicians [5]. Private equity firms are targeting urology practices due to their recurring revenue streams, high-margin procedures, and market fragmentation, according to Dykema’s 2026 M&A Outlook Survey [5]. This trend risks reducing patient choice and increasing costs, as consolidated groups may prioritize profit over community-based care. LUGPA’s 2026 Annual Meeting in Chicago focused on helping independent practices navigate these challenges, offering sessions on ancillary revenue streams, benchmarking metrics, and AI integration to enhance operational efficiency [5][1].
Innovation and Advocacy as Survival Strategies
In response to these pressures, independent urology practices are turning to innovation and advocacy to safeguard their future. At LUGPA’s meeting, sessions highlighted the integration of AI tools to reduce administrative burdens, such as ambient digital scribes and AI-assisted pathology, as well as the adoption of advanced therapies like theranostics for prostate cancer [1]. The meeting also featured a bipartisan policy keynote with former New Jersey Governor Chris Christie and political strategist David Axelrod, who provided insights into federal regulatory shifts impacting physician autonomy [1]. Celeste Kirschner, CAE, MHSA, LUGPA’s CEO, emphasized the importance of peer-to-peer knowledge sharing, stating that the meeting equips practices with the ‘essential toolkit for independent urology to thrive’ [1]. Meanwhile, LUGPA’s incoming president, Jeffrey Spier, MD, stressed the need to translate clinical science and policy into practical solutions for day-to-day operations [1].
The Road Ahead: Legislative and Operational Priorities
Looking to 2027, LUGPA has outlined a robust advocacy agenda, including addressing the Medicare conversion factor cut, pushing for prior authorization reform, and tackling workforce shortages. The organization is particularly focused on averting the Part B drug price negotiation policy, which threatens to erode practice margins based on the average sales price (ASP) plus a 4.3% markup [3]. LUGPA is pushing for a bipartisan solution involving a pharmaceutical rebate system to ensure physicians are not financially disadvantaged [3]. However, the path forward is uncertain due to ongoing gridlock in Congress. Kirsh cautioned that health policy advocacy is ‘a very long game,’ requiring sustained effort over years to achieve meaningful change [3]. For independent practices, the immediate priorities remain tightening coding practices, auditing high-volume procedures, and benchmarking against LUGPA metrics to improve revenue cycle efficiency [5].